BioEclipse Therapeutics
Early Stage
Clinical-stage immunotherapy
Overview
Raised: $0
Total Commitments ($USD)
Platform
Netcapital
Start Date
01/19/2022
Close Date
04/19/2022
Min. Goal
$10,001
Max. Goal
$1,069,998
Min. Investment
$99
Security Type
Equity - Common
Series
Seed
SEC Filing Type
RegCF
Price Per Share
$2.55
Pre-Money Valuation
$28,993,373
Rolling Commitments ($USD)
Status
Not Funded
Reporting Date
04/24/2022
Days Remaining
Not Funded
% of Min. Goal
Not Funded
% of Max. Goal
Not Funded
Likelihood of Max
Not Funded
Avg. Daily Raise
$0
Momentum
Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2006
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
BioEclipse Therapeutics, with a valuation of $28.99 million, is raising funds on NetCapital. It is an immunotherapy company using its proprietary technology platform to combine the power of an oncolytic virus with the tumor-locating ability of CIK cells. The technology helps BioEclipse Therapeutics in developing the next generation of immuno-oncology therapeutics. BioEclipse Therapeutics is led by an experienced team and has CRX100 clinical trials underway. Pamela Contag founded BioEclipse Therapeutics in May 2006. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,069,998. The campaign proceeds will be used for compensation, rent, research, and lab supplies.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-4,391,188 |
$-2,415,736 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$2,331,499 |
$5,394,836 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$2,956,073 |
$5,839,337 |
|
Short-Term Debt |
$75,862 |
$0 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$75,862 |
$0 |
Financials as of: 01/19/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.